Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 2,328 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PET (Positron Emission Tomography) Clear all

Conditions: Alzheimer Dementia, Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions: MRI, PET, 18F-Florbetapir, Radioligand 18F-AV-1451; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alcohol Use Disorder
Interventions: [18F]NOS; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Interventions: Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan, Biospecimen Collection, Electronic Health Record Review; Drug · Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Carcinoma, Recurrent Prostate Carcinoma
Interventions: 99mTc-based PSMA Imaging and Surgery Agent, Computed Tomography, Single Photon Emission Computed Tomography; Drug · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Microvascular Coronary Dysfunction
Interventions: Mental Stress Testing, Peripheral Arterial Tonometry (PAT) Testing, Heart Rate Variability (HRV), RESPeRATE Breathing Trial, SPECT cardiac scan with 123I-mIBG and Myoview; Behavioral · Other · Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers, Amyotrophic Lateral Sclerosis
Interventions: [18F]PBR06; Drug
Lead sponsor: Molecular NeuroImaging; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastasis Colon Cancer, Colorectal Cancer
Interventions: Y90 TARE, PET/CT, PET/MRI; Radiation · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Melanoma
Interventions: [18F] CFA; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel, FDG-PET, V/Q SPECT, Durvalumab; Radiation · Drug · Device
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Epilepsy, Temporal Lobe
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Dexamethasone, FDG-Positron Emission Tomography, Fludeoxyglucose F-18, Pomalidomide, Teclistamab; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer
Interventions: Imaging Drug FluorThanatrace (FTT); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostatic Neoplasms
Interventions: FACBC PET-CT Scan, Three-dimensional ultrasound-guided biopsy, Standard transrectal ultrasound (TRUS) guided biopsy; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder
Interventions: Ketamine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Impaired Cognition, Chemo-brain, Breast Cancer
Interventions: Cognitive, functional and subjective assessments, MRI, PET Scan; Other · Device · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: Renal Cell Carcinoma
Interventions: 89Zr-DFO-Atezolizumab, Positron Emission Tomography/Computed Tomography; Drug · Procedure
Lead sponsor: James Brugarolas; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
Interventions: Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography, Fludeoxyglucose F-18, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography, Resection; Procedure · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Renal Cell Carcinoma
Interventions: 150-Water, 62Cu-ethylglyoxal bis, Positron Emission Tomography, Sunitinib; Drug · Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease
Interventions: 18F-AV-133, 18F-AV-45; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Sun City, Arizona • Philadelphia, Pennsylvania

Conditions: Coronary Artery Disease
Interventions: [O-15]-Water PET Myocardial Perfusion Imaging (MPI); Drug
Lead sponsor: MedTrace Pharma A/S; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Iowa City, Iowa • Rochester, Minnesota • St Louis, Missouri + 3 more

Conditions: Healthy
Interventions: [11C]JMJ-129-d2; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 105 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Normal Physiology, Opioid Use Disorders
Interventions: [11C]raclopride plus placebo, [11C]raclopride plus drug, [11C]NNC-112; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer
Interventions: Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: Lawrence Fong; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics

PET Imaging in Parkinson Disease Dementia

Imaging Inflammation With Alcohol Use Disorder: an [18F]NOS Study

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Cardiac Autonomic Function in Women with Microvascular Coronary Dysfunction

Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

PET Imaging of the Immune System Using Analog Probes

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Study of [11C]DPA-713 for Temporal Lobe Epilepsy

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT

Targeted Fusion Biopsy of the Prostate

Ketamine Treatment Effects on Synaptic Plasticity in Depression

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE4D Imaging in Healthy Volunteers

Brain Dopaminergic Signaling in Opioid Use Disorders

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1